These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38697461)

  • 1. Oncogenic functions and therapeutic potentials of targeted inhibition of SMARCAL1 in small cell lung cancer.
    Sun BB; Wang GZ; Han SC; Yang FY; Guo H; Liu J; Liu YT; Zhou GB
    Cancer Lett; 2024 Jun; 592():216929. PubMed ID: 38697461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of SMARCAL1 as a molecular target for small cell lung cancer treatment.
    Jiang Y; Li S; Ramesh R
    Cancer Lett; 2024 Jun; 592():216932. PubMed ID: 38735383
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
    Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
    Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
    Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
    Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of HELLS by miR-451a represses mTOR pathway to hinder aggressiveness of SCLC.
    Cui J; Wang J; Shen Y; Lin D
    Genes Genomics; 2021 Feb; 43(2):105-114. PubMed ID: 33460027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
    Ramkumar K; Tanimoto A; Della Corte CM; Stewart CA; Wang Q; Shen L; Cardnell RJ; Wang J; Polanska UM; Andersen C; Saeh J; Pease JE; Travers J; Fabbri G; Gay CM; Urosevic J; Byers LA
    Clin Cancer Res; 2023 Aug; 29(16):3237-3249. PubMed ID: 37289191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
    Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
    Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models.
    Sun D; Nikonova AS; Zhang P; Deneka AY; Fitzgerald ME; Michael RE; Lee L; Lilly AC; Fisher SL; Phillips AJ; Nasveschuk CG; Proia DA; Tu Z; Golemis EA
    Mol Cancer Ther; 2021 Aug; 20(8):1367-1377. PubMed ID: 34045230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 16. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
    Wang J; Sun T; Meng Z; Wang L; Li M; Chen J; Qin T; Yu J; Zhang M; Bie Z; Dong Z; Jiang X; Lin L; Zhang C; Liu Z; Jiang R; Yang G; Li L; Zhang Y; Huang D
    Cancer Lett; 2021 Apr; 503():197-212. PubMed ID: 33493586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
    Huang J; Cao D; Sha J; Zhu X; Han S
    Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
    Giffin MJ; Cooke K; Lobenhofer EK; Estrada J; Zhan J; Deegen P; Thomas M; Murawsky CM; Werner J; Liu S; Lee F; Homann O; Friedrich M; Pearson JT; Raum T; Yang Y; Caenepeel S; Stevens J; Beltran PJ; Canon J; Coxon A; Bailis JM; Hughes PE
    Clin Cancer Res; 2021 Mar; 27(5):1526-1537. PubMed ID: 33203642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors.
    Kawabata S; Connis N; Gills JJ; Hann CL; Dennis PA
    Anticancer Res; 2021 Jan; 41(1):91-99. PubMed ID: 33419802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting SMARCAL1 as a novel strategy for cancer therapy.
    Zhang L; Fan S; Liu H; Huang C
    Biochem Biophys Res Commun; 2012 Oct; 427(2):232-5. PubMed ID: 22995303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.